Fig. 4

Palmatine inhibits PI3K/AKT pathway and increases PTEN activity in an in vivo CMT-U27 xenograft models. Tumors of CMT-U27 xenograft model injected with palmatine (treatment group) or DMSO in PBS (control group) for 21 days were collected and western blotting was performed. A-D Images and quantification of the protein expression of p-PI3K (A), p-PTEN (B), p-AKT (C), p-mTOR (D) and β-actin in tumors. Values are mean ± SD. *** p < 0.001 versus control by unpaired Student’s t-test. Con., control; Pal., palmatine